Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 25.15
- Piotroski Score 4.00
- Grade Buy
- Symbol (CMPX)
- Company Compass Therapeutics, Inc.
- Price $1.39
- Changes Percentage (1.09%)
- Change $0.02
- Day Low $1.34
- Day High $1.41
- Year High $2.34
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.35
- Trailing P/E Ratio -3.74
- Forward P/E Ratio -3.74
- P/E Growth -3.74
- Net Income $-42,494,000
Income Statement
Quarterly
Annual
Latest News of CMPX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
Investing in unprofitable companies like Salesforce.com can be profitable, but caution is advised due to the risk of cash burn. Compass Therapeutics (NASDAQ:CMPX) had a 3.7-year cash runway as of Marc...
By Yahoo! Finance | 4 months ago
